Key Developments: Celgene Corp (CELG.O)

CELG.O on Nasdaq

117.66USD
26 Mar 2015
Change (% chg)

-- (--)
Prev Close
$117.66
Open
--
Day's High
--
Day's Low
--
Volume
17
Avg. Vol
5,384,769
52-wk High
$129.06
52-wk Low
$66.85

Search Stocks

Latest Key Developments (Source: Significant Developments)

Health Canada Approves Celgene Corp 's ABRAXANE Plus Gemcitabine for first-line treatment of patients with metastatic pancreatic cancer
Wednesday, 6 Aug 2014 08:00am EDT 

Celgene Corp:Says Health Canada has approved ABRAXANE for Injectable Suspension (paclitaxel powder for injectable suspension) (nanoparticle, albumin-bound [nab] paclitaxel) for first-line treatment of adult patients with metastatic pancreatic cancer.Approval is welcome news for Canadians who are diagnosed with metastatic pancreatic cancer, and represents first approved treatment for this disease in nearly two decades.Health Canada approval was based on results of MPACT, an open-label, phase III, randomized, international study which was published in New England Journal of Medicine in Oct. 2013.  Full Article

Celgene Corp raises FY 2014 guidance
Thursday, 24 Jul 2014 07:32am EDT 

Celgene Corp:Raised FY 2014 total revenue to about $7.6 bln from $7. bln.Raised FY 2014 adjusted diluted EPS to a range of $3.60 to $3.65 from the previous range of $3.50 to $3.60, an increase of about 22 pct over 2013 adjusted diluted EPS.FY 2014 GAAP diluted EPS is expected to be in the range of $2.46 to $2.55 from the previous range of $2.47 to $2.59.FY 2014 revenue of $7.53 bln and EPS of $3.67 - Thomson Reuters I/B/E/S.  Full Article

Celgene reports results from phase III POSTURE Study Evaluating Oral OTEZLA in Ankylosing Spondylitis
Wednesday, 9 Jul 2014 07:00am EDT 

Celgene Corp:Declares results of its phase III POSTURE study evaluating OTEZLA, the company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), in patients with active ankylosing spondylitis.OTEZLA arms did not achieve statistical improvement versus the placebo arm for the primary endpoint, the percentage of patients who achieve an ASAS (Assessment of SpondyloArthritis international Society) 20 response at week 16.Evaluation of the efficacy results is ongoing.  Full Article

Celgene Corp reaffirms FY 2017 revenue guidance - Conference Call
Wednesday, 11 Jun 2014 01:00pm EDT 

Celgene Corp:Expects FY 2017 revenue of $13 billion to $14 billion overall.FY 2017 revenue of $13 billion - Thomson Reuters I/B/E/S.  Full Article

Celgene Corp's subsidiary updates phase III clinical trials of OTEZLA
Wednesday, 11 Jun 2014 07:30am EDT 

Celgene Corp:Says a subsidiary Celgene International Sarl, results of additional analyses from the phase III clinical trials of OTEZLA, the company's oral, selective inhibitor of phosphodiesterase 4 (PDE4).These included long-term (52-week) analyses from the PALACE 1, 2 and 3 trials of the impact of OTEZLA on psoriatic arthritis disease activity, safety and tolerability, in addition to a separate 16-week work productivity analysis from PALACE 1.The findings were presented at the European League Against Rheumatism Annual Congress (EULAR 2014) in Paris, France.  Full Article

Celgene announces appointment of Chief Financial Officer
Thursday, 22 May 2014 06:00am EDT 

Celgene Corp:Appoints Peter Kellogg as Executive Vice President, Chief Financial Officer.  Full Article

Celgene Corp gives FY 2017 revenue guidance in line with analysts' estimates - Conference Call
Monday, 19 May 2014 01:30pm EDT 

Celgene Corp:Says for FY 2017 it expect $13 billion to $14 billion in sales by that period of time.FY 2017 revenue of $13.14 billion - Thomson Reuters I/B/E/S.  Full Article

Celgene announces public offering of Senior Notes due 2019, 2024 and 2044 - Form 8-K
Wednesday, 7 May 2014 02:18pm EDT 

Celgene Corp:Announces underwritten public offering of $500 mln aggregate principal amount of 2.250pct Senior Notes due 2019, $1 bln aggregate principal amount of 3.625pct Senior Notes due 2024 and $1 bln aggregate principal amount of 4.625pct Senior Notes due 2044.Intends to use the net proceeds for general corporate purposes.Merrill Lynch, Pierce, Fenner & Smith Incorporated, Credit Suisse Securities (USA) LLC, Goldman, Sachs & Co. and Morgan Stanley & Co. LLC acts as underwriters.  Full Article

Celgene Corp reaffirms long term outlook - Conference Call
Wednesday, 7 May 2014 10:10am EDT 

Celgene Corp:Says looking out to FY 2017 it estimated top line all in for franchises of $13 -$14 bln with a bottom line opportunity of up to $15 in EPS.FY 2017 revenue of $13 bln, EPS of $15 - Thomson Reuters I/B/E/S.  Full Article

Celgene Corp announces offering of senior unsecured notes
Tuesday, 6 May 2014 08:30am EDT 

Celgene Corp:Intention to offer senior unsecured notes under shelf registration statement on Form S-3 on file with Securities and Exchange Commission.Interest rate, the maturity dates and other key terms of the offering are to be determined at time of pricing.Expects to use net proceeds for general corporate purposes.  Full Article

Morphosys, Celgene end cooperation on MOR202 drug candidate

FRANKFURT - Morphosys and Celgene have agreed to end their cooperation on MOR202, but clinical trials of the drug candidate will continue, Morphosys said on Thursday.

Search Stocks